Stoke Therapeutics Q2 2023 net loss $30.7M; cash $231.4M to fund operations to end of 2025

Stoke Therapeutics, Inc.

2023-Q2 EPS reported -$1.23 revenue$2,671,000

Net loss $30.7M ($0.69 per share) vs $24.7M ($0.63) in Q2 2022; R&D expenses $20.6M.
Cash and marketable securities $231.4M as of June 30, 2023; expected runway to end of 2025.
Revenue reversed $(2.5)M vs $3.2M a year ago due to $5.3M cumulative catch-up on Acadia collaboration.
STK-001: additional data from MONARCH/ADMIRAL and OLEs expected Q1 2024 to inform Phase 3 design.
STK-002: UK MHRA authorized Phase 1 OSPREY study for ADOA; enrollment in FALCON natural history completed (n=48).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Stoke Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-038733

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.